Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BDRX

Biodexa Pharmaceuticals (BDRX)

Biodexa Pharmaceuticals PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BDRX
DateTimeSourceHeadlineSymbolCompany
22/05/202422:30GlobeNewswire Inc.Biodexa Announces $7 Million of Gross Proceeds from Warrant ExercisesNASDAQ:BDRXBiodexa Pharmaceuticals PLC
21/05/202422:30GlobeNewswire Inc.Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual MeetingNASDAQ:BDRXBiodexa Pharmaceuticals PLC
15/05/202417:57GlobeNewswire Inc.Posting of Annual Report & Notice of AGM - Total Voting RightsNASDAQ:BDRXBiodexa Pharmaceuticals PLC
01/05/202401:51GlobeNewswire Inc.Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual MeetingNASDAQ:BDRXBiodexa Pharmaceuticals PLC
26/04/202422:30GlobeNewswire Inc.Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)NASDAQ:BDRXBiodexa Pharmaceuticals PLC
19/04/202422:00GlobeNewswire Inc.Preliminary Results for the Year Ended 31 December 2023NASDAQ:BDRXBiodexa Pharmaceuticals PLC
24/02/202400:30GlobeNewswire Inc.Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D UpdateNASDAQ:BDRXBiodexa Pharmaceuticals PLC
14/02/202400:15AllPennyStocks.comBiotech Shares Bid Up Premarket Following 9.9% Institutional Stake DisclosureNASDAQ:BDRXBiodexa Pharmaceuticals PLC
09/02/202400:30GlobeNewswire Inc.Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma PatientsNASDAQ:BDRXBiodexa Pharmaceuticals PLC
08/02/202400:30GlobeNewswire Inc.Biodexa Announces Allowance of U.S. Patent Covering TolimidoneNASDAQ:BDRXBiodexa Pharmaceuticals PLC
23/01/202400:30GlobeNewswire Inc.Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024NASDAQ:BDRXBiodexa Pharmaceuticals PLC
29/12/202320:05GlobeNewswire Inc.Biodexa Appoints Ann Merchant to the Board of DirectorsNASDAQ:BDRXBiodexa Pharmaceuticals PLC
22/12/202308:00GlobeNewswire Inc.Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment OptionNASDAQ:BDRXBiodexa Pharmaceuticals PLC
20/12/202300:42GlobeNewswire Inc.Biodexa Announces Pricing of $5.2 Million Underwritten Public OfferingNASDAQ:BDRXBiodexa Pharmaceuticals PLC
28/11/202301:00GlobeNewswire Inc.Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 DiabetesNASDAQ:BDRXBiodexa Pharmaceuticals PLC
03/10/202323:30GlobeNewswire Inc.Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent GlioblastomaNASDAQ:BDRXBiodexa Pharmaceuticals PLC
30/09/202306:30GlobeNewswire Inc.Interim results for the six months ended 30 June 2023NASDAQ:BDRXBiodexa Pharmaceuticals PLC
21/09/202322:30GlobeNewswire Inc.Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)NASDAQ:BDRXBiodexa Pharmaceuticals PLC
28/07/202322:00GlobeNewswire Inc.Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials WebsitesNASDAQ:BDRXBiodexa Pharmaceuticals PLC
24/07/202321:30GlobeNewswire Inc.Biodexa Regain Compliance with NASDAQ Minimum Bid Price RequirementNASDAQ:BDRXBiodexa Pharmaceuticals PLC
10/07/202322:00GlobeNewswire Inc.Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (DMGs)NASDAQ:BDRXBiodexa Pharmaceuticals PLC
07/07/202306:30GlobeNewswire Inc.Results of Appeal of Delisting DeterminationNASDAQ:BDRXBiodexa Pharmaceuticals PLC
06/07/202322:15GlobeNewswire Inc.Publication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG)NASDAQ:BDRXBiodexa Pharmaceuticals PLC
23/06/202306:15GlobeNewswire Inc.ADR Ratio ChangeNASDAQ:BDRXBiodexa Pharmaceuticals PLC
20/06/202322:00GlobeNewswire Inc.Appeal of Delisting DeterminationNASDAQ:BDRXBiodexa Pharmaceuticals PLC
16/06/202306:05GlobeNewswire Inc.Receipt of NASDAQ Delisting Determination Plans to AppealNASDAQ:BDRXBiodexa Pharmaceuticals PLC
14/06/202322:30GlobeNewswire Inc.Results of Annual General Meeting and General MeetingNASDAQ:BDRXBiodexa Pharmaceuticals PLC
27/05/202306:05GlobeNewswire Inc.Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct OfferingNASDAQ:BDRXBiodexa Pharmaceuticals PLC
24/05/202322:40GlobeNewswire Inc.Biodexa Pharmaceuticals PLC Announces US$3.32 Million Registered Direct OfferingNASDAQ:BDRXBiodexa Pharmaceuticals PLC
23/05/202306:15GlobeNewswire Inc.Posting of Annual Report & Notice of AGMNASDAQ:BDRXBiodexa Pharmaceuticals PLC
 Showing the most relevant articles for your search:NASDAQ:BDRX

Your Recent History